# Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
Canonical URL: https://biopharmsignal.com/news/INVA/innoviva-reports-fourth-quarter-and-full-year-2025-financial-results-highlights-recent-company-progress
Ticker: INVA
Company: Innoviva
Source: Innoviva
Published: 2026-02-25 21:05 EST
Original Source URL: https://investor.inva.com
## Summary

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth IST product portfolio

## Article Body
Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth IST product portfolio
## Recent Company News
- 2026-05-06 20:05 EST — [Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress](https://biopharmsignal.com/news/INVA/innoviva-reports-first-quarter-2026-financial-results-highlights-recent-company-progress) — Source: Innoviva
- 2026-02-25 21:05 EST — [Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress](https://biopharmsignal.com/news/INVA/innoviva-reports-fourth-quarter-and-full-year-2025-financial-results-highlights-recent-company-progress) — Source: Innoviva
- 2026-02-19 13:00 EST — [Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference](https://biopharmsignal.com/news/INVA/innoviva-to-participate-in-the-oppenheimer-36th-annual-healthcare-life-sciences-conference) — Source: Innoviva
- 2025-12-12 21:56 EST — [U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents](https://biopharmsignal.com/news/INVA/u-s-fda-approves-nuzolvencer-zoliflodacin-a-first-in-class-single-dose-oral-antibiotic-for-the-treatment-of-uncomplicated-urogenital-gonorrhea-in-adults-and-adolescents) — Source: Innoviva
- 2025-12-11 23:35 EST — [Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea](https://biopharmsignal.com/news/INVA/innoviva-specialty-therapeutics-announces-publication-in-the-lancet-of-positive-zoliflodacin-phase-3-data-for-the-treatment-of-uncomplicated-urogenital-gonorrhea) — Source: Innoviva
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)